Samsung Life Insurance (032830) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
21 May, 2026Executive summary
Net income for Q1 2026 surged 89.5%–90% year-over-year to KRW 1,203.6 billion, driven by stable insurance earnings, higher dividend income, and increased equity method and consolidated earnings from subsidiaries and associates.
New business CSM increased 11% quarter-over-quarter to KRW 848.6 billion, with balanced growth across exclusive and non-exclusive channels.
CSM balance reached KRW 13.6 trillion, up KRW 0.4 trillion year-to-date, supported by solid new business and stable insurance efficiency management.
Shareholders' equity increased by KRW 18.5 trillion year-to-date, supported by robust profit generation and higher SEC share price.
Financial highlights
Loss ratio maintained at 85%, in line with business plan.
K-ICS ratio stood at 210% at quarter-end, up 12 percentage points from year-end, reflecting growth in CSM, earnings expansion, and favorable equity and interest rate movements.
Trust AUM for death claim products reached KRW 560 billion.
Investment profits rose 125.5% year-over-year, mainly from dividend income and subsidiary contributions.
Insurance service results declined 7.7% year-over-year due to negative operating variance.
Outlook and guidance
Commitment to stable and sustainable dividend growth per share, with a mid- to long-term payout target of 50%.
Open to spreading out special dividend distributions over multiple years if large-scale non-recurring profits are realized.
Focus on enhancing corporate value through higher dividends and improved operating ROE.
Continued focus on disciplined ALM management and strategic asset allocation amid changing macroeconomic and geopolitical conditions.
Latest events from Samsung Life Insurance
- H1 2026 net profit up 35.8% to KRW 1.97T, with strong capital and diversified segment growth.032830
Q2 2026 - FY2025 net profit rose 9.3% to KRW 2.3T, with record CSM and DPS up 18%; strong 2026 growth targeted.032830
Q4 2025 - Net profit up 3.7% YoY, with strong capital, health CSM growth, and higher equity.032830
Q3 2025 - H1 2025 net profit up 1.9% to KRW 1.394T, KICS at 187%, assets KRW 319.1T, ESG AA.032830
Q2 2025 - Q3 net profit up 41.6% YoY, strong health insurance and capital, CSM at ₩13 trillion.032830
Q3 2024 - Net profit up 40.5% to KRW 1.37T in H1 2024; health CSM leads; 50% payout ratio targeted.032830
Q2 2024 - Q1 2025 net profit reached KRW 677.5B, assets KRW 318.9T, solvency margin 218.8%.032830
Q1 2025 - Record profit, robust capital, and higher dividends driven by health segment growth.032830
Q4 2024